President, Sonia express concern over lynching incidents

Agencies
July 2, 2017

New Delhi, Jul 2: President Pranab Mukherjee joined Congress president Sonia Gandhi in expressing serious concern over growing number of mob lynching cases in India, wondering whether the society is vigilant enough to save the basic tenets of the country.

sonia

“When mob lynching becomes so high and uncontrollable, we have to pause and reflect, are we vigilant enough?,” Mukherjee said at the release of commemorative publication of relaunched National Herald here.

Sonia Gandhi, who spoke at the function, said, "It is being encouraged by a culture of vigilante violence, actively supported by those who are supposed to enforce the law."

Later, Priyanka Gandhi Vadra, daughter of the Congress president, told reporters that "It (incident of lynching) makes my blood boil. It should make blood of every Indian boil."

Mukherjee's comment and Sonia Gandhi's criticism came in the wake of reports about the spiralling violence over beef.

Mukherjee, who retires later this month, said, "When mob frenzy becomes so high, irrational and uncontrollable, we have to pause and reflect. I am not talking of vigilantism, I am talking of are we vigilant enough, proactively to save the basic tenets of our country.”

He said, "I do believe that citizens' and media vigilance can act as the biggest deterrent to forces of darkness and backwardness."

Congress president Sonia Gandhi said India is being marked by increasing threats of 'authoritarianism.'

She said, "Today the tried and tested idea of India has been thrown fundamentally into question by rising intolerance, by malevolent forces. It is being encouraged by a culture of vigilantive violence, actively supported by those who are supposed to enforce the law."

Gandhi further said that National Herald newspaper, which has been revived, is a testament to unity and justice and "not the division and hate that the present times are witnessing.

She said, "We are in a war of ideas, we have reached this war to preserve our ideas, which have built India as a model of democracy diversity and coexistence.if we don't raise our voices, if we do not speak up, our voices will be taken as consent."

A day after nationwide protests against lynchings spilt onto the streets, Modi had on Thursday broke his silence at Sabarmati Ashram in Gujarat and said killing people in the name of gau bhakti (devotion to the cow) is not acceptable.

The PM also said Mahatma Gandhi would not have approved of it and that no person in the country has the right to take the law into his own hands.

However, Modi's warning seemed to have had a little effect as just hours after his speech, Alimuddin, a meat trader, was lynched in Jharkhand’s Ramgarh.

Many cities witnessed protests across various locations under the tagline “Not in My Name” to protest against the lynching of 15-year-old Junaid Khan in a Mathura-bound train last week.

Comments

AK
 - 
Thursday, 6 Jul 2017

Thats VERY VERY GOOD .. Many families will give blessing to siddaramaiah...

Only Drunkards will not be happy with the closer.

Abdullah
 - 
Sunday, 2 Jul 2017

Worst President and opposition party ever faced in India.

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 3,2020

New Delhi, Jun 3: India registered its highest single-day spike in COVID-19 cases on Wednesday with 8,909 more cases reported in the last 24 hours, taking the country's tally to 2,07,615, while the death toll rose to 5,815 according to the Union Health and Family Welfare Ministry.

The number of active COVID-19 cases stood to 1,01,497 while 1,00,303 people have been cured/discharged/migrated.

According to the Union Health and Family Welfare Ministry, out of all the states, Maharashtra has recorded the highest number of coronavirus cases with 72,300 patients followed by Tamil Nadu with 24,586 cases.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 31,2020

New Delhi, Jan 31: The central government has decided that pensioners' life certificates will be collected from their doorstep, saving them from hassles of visiting pension disbursing banks.

The service will be charged an amount not exceeding Rs 60, according to a statement issued on Thursday by the Department of Pension and Pensioners' Welfare (DoPPW).

Every year a pensioner is required to give proof of him being alive to banks in order to ensure continued pension. These certificates can be submitted online or by visiting the bank.

"The department has taken a landmark step to make life easier for senior citizens to submit their annual life certificate for continued pension," it said.

Directions have been issued to all pension disbursing banks to send SMS or emails to all their pensioners on October 24, November 1, November 15 and November 25 every year reminding them to submit their annual life certificates by November 30, the statement said.

"The bank in addition will also ask such pensioners through SMS/email as to whether they are interested in submission of life certificate through a chargeable doorstep service, the charge not exceeding Rs 60, it said.

The department for stricter monitoring and in order to ensure that no pensioners are left out has also directed the banks to make an exception list on December 1 every year of those pensioners who fail to submit their life certificate and issue another SMS or email to them for submitting it.

The Central Pension Processing Cells (CPPC) of the pension disbursing banks shall now be duty bound to submit a report to the DoPPW in January, February and March.

The report will indicate the total number of pensioners who have not given their life certificate along with a breakup of the certificates submitted physically and through digital means, the statement said.

This is a landmark step from the side of the central government showing due care for pensioners, it said.

This step is in addition to the order issued in July last year, vide which all pensioners aged 80 years and above have been given an exclusive window to submit their life certificate w.e.f. 1st October every year instead of 1st November every year, the statement added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed Covid-19 vaccine candidate in the country.

Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on Covid-19.

"The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.

"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said.

As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, 'Covishield', on healthy adults in India,  the officials said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.

The officials said that the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of 'Covishield' on healthy Indian adults," the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for Covid-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine. 

Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said.

To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.